Moderna (MRNA) Cash from Operations Growth (3y) (2021 - 2026)
Powered by 
Analysis
Moderna (MRNA) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -0.88% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 15.19% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -0.27% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -7.35% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 16.85% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 96.08% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -2.68% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 10.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.85% |
| Mar 31, 2026 | 19.88% |
| Dec 31, 2025 | -17.60% |
| Sep 30, 2025 | -75.02% |
| Jun 30, 2025 | -71.26% |
| Mar 31, 2025 | -33.43% |
| Dec 31, 2024 | -37.07% |
| Sep 30, 2024 | -35.32% |
| Jun 30, 2024 | -32.26% |
| Mar 31, 2024 | -32.63% |
| Dec 31, 2023 | -21.05% |
| Sep 30, 2023 | -55.94% |
| Jun 30, 2023 | -236.57% |
| Mar 31, 2023 | -126.09% |
| Dec 31, 2022 | 165.80% |
| Sep 30, 2022 | 63.28% |
| Jun 30, 2022 | 68.68% |
| Mar 31, 2022 | 176.56% |
| Dec 31, 2021 | 237.27% |
| Sep 30, 2021 | 249.91% |